secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001159036-24-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q4 revenue $230M (+27% YoY); reiterates 2024 guidance; $750M buyback
-----------------------------------------------------------------------------

- Q4 revenue $230M (+27% YoY); GAAP EPS $0.65, non-GAAP EPS $0.82; FY23 revenue $829M (+26%).
- 2024 guidance: revenue $915-985M (10-19% growth), non-GAAP EPS $3.55-3.90 (28-41% growth).
- New $750M share repurchase program announced, reflecting confidence in growth.
- Partner milestones: argenx VYVGART Hytrulo FDA priority review for CIDP (PDUFA June 21); $23M milestone.
- Roche's Tecentriq SC received EU approval; Takeda's HYQVIA approved for CIDP in US and EU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/halo-20240220.htm
  HTML page:      https://secwatch.observer/filing/0001159036-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer